Tempus AI reports preliminary FY2025 revenue ~$1.27B (+83% YoY); TCV exceeds $1.1B

Tempus AI, Inc.

2025-FY EPS reported -$1.41 vs consensus -$0.04 ▼ miss (-3241.2%)

FY2025 revenue ~$1.27B (+83% YoY); diagnostics ~$955M (+111%), data/apps ~$316M (+31%).
Q4 2025 revenue ~$367M (+83% YoY); diagnostics ~$266M (+121%), data/apps ~$100M (+25%).
Record total contract value >$1.1B as of Dec 31, 2025; net revenue retention ~126%.
Signed data agreements with >70 customers including AstraZeneca, Pfizer, Novartis, Merck, Eli Lilly, etc.
Preliminary results subject to change; final earnings call in Feb 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.